CN107531696B - 作为nmda受体调节剂的吡啶并嘧啶酮类及它们的用途 - Google Patents

作为nmda受体调节剂的吡啶并嘧啶酮类及它们的用途 Download PDF

Info

Publication number
CN107531696B
CN107531696B CN201680021960.3A CN201680021960A CN107531696B CN 107531696 B CN107531696 B CN 107531696B CN 201680021960 A CN201680021960 A CN 201680021960A CN 107531696 B CN107531696 B CN 107531696B
Authority
CN
China
Prior art keywords
methyl
pyrido
pyrimidin
trifluoromethyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680021960.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107531696A (zh
Inventor
马修·沃尔格拉夫
蒋宇
伊莱沙·维尔缪
本杰明·塞勒斯
吴国胜
陆爱军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN107531696A publication Critical patent/CN107531696A/zh
Application granted granted Critical
Publication of CN107531696B publication Critical patent/CN107531696B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680021960.3A 2015-04-15 2016-04-12 作为nmda受体调节剂的吡啶并嘧啶酮类及它们的用途 Active CN107531696B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/076617 2015-04-15
CN2015076617 2015-04-15
PCT/EP2016/057962 WO2016166078A1 (en) 2015-04-15 2016-04-12 Pyridopyrimidinones and their use as nmda receptor modulators

Publications (2)

Publication Number Publication Date
CN107531696A CN107531696A (zh) 2018-01-02
CN107531696B true CN107531696B (zh) 2021-03-16

Family

ID=55809078

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680021960.3A Active CN107531696B (zh) 2015-04-15 2016-04-12 作为nmda受体调节剂的吡啶并嘧啶酮类及它们的用途

Country Status (19)

Country Link
US (1) US10280165B2 (https=)
EP (1) EP3283487B1 (https=)
JP (2) JP6847851B2 (https=)
KR (1) KR20170137137A (https=)
CN (1) CN107531696B (https=)
AU (1) AU2016248886B2 (https=)
BR (1) BR112017021083A2 (https=)
CA (1) CA2982217A1 (https=)
CL (1) CL2017002498A1 (https=)
CO (1) CO2017009989A2 (https=)
CR (1) CR20170462A (https=)
IL (1) IL254921B (https=)
MX (1) MX373162B (https=)
PE (1) PE20180316A1 (https=)
PH (1) PH12017501876A1 (https=)
RU (1) RU2717665C2 (https=)
SG (1) SG11201708294YA (https=)
UA (1) UA120647C2 (https=)
WO (1) WO2016166078A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016004540A (es) 2013-10-11 2016-07-21 Hoffmann La Roche Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
EP3283487B1 (en) 2015-04-15 2019-10-16 H. Hoffnabb-La Roche Ag Pyridopyrimidinones and their use as nmda receptor modulators
SMT202000534T1 (it) 2015-12-09 2020-11-10 Cadent Therapeutics Inc Modulatori eteroaromatici del recettore nmda e loro usi
ES2975336T3 (es) 2016-12-22 2024-07-04 Novartis Ag Moduladores del receptor NMDA y usos de los mismos
BR112021001967A2 (pt) 2018-08-03 2021-04-27 Cadent Therapeutics, Inc. moduladores de receptor nmda heteroaromáticos e usos dos mesmos
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
PE20230609A1 (es) 2020-05-04 2023-04-13 Amgen Inc Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2004113335A2 (en) * 2003-06-20 2004-12-29 Chiron Corporation Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
AR065194A1 (es) * 2007-02-05 2009-05-20 Xenon Pharmaceuticals Inc Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio
JP6130061B2 (ja) * 2013-06-19 2017-05-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ インドリン−２−オン又はピロロ−ピリジン／ピリミジン−２−オン誘導体
MX2016004540A (es) * 2013-10-11 2016-07-21 Hoffmann La Roche Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
EP3283487B1 (en) 2015-04-15 2019-10-16 H. Hoffnabb-La Roche Ag Pyridopyrimidinones and their use as nmda receptor modulators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"RN:1325984-61-9";STN-Registry数据库;《ACS》;20110831;全文 *
"RN：1627306-85-7";STN-Registry数据库;《ACS》;20140928;全文 *
New 2-Substituted 1,2,3,4-Tetrahydrobenzofuro[3,2-c]pyridineHaving Highly Active and Potent Central _2-Antagonistic Activity as Potential Antidepressants;Ludo E. J. Kennis;《Bioorganic & Medicinal Chemistry Letters》;20001231;第10卷(第1期);table1 *
RN:875421-49-1;STN-Registry数据库;《ACS》;20060228;全文 *

Also Published As

Publication number Publication date
UA120647C2 (uk) 2020-01-10
AU2016248886A1 (en) 2017-10-12
RU2017139254A (ru) 2019-05-15
CR20170462A (es) 2018-02-01
JP2021046428A (ja) 2021-03-25
RU2717665C2 (ru) 2020-03-24
PE20180316A1 (es) 2018-02-09
JP2018511627A (ja) 2018-04-26
RU2017139254A3 (https=) 2019-09-30
US10280165B2 (en) 2019-05-07
EP3283487B1 (en) 2019-10-16
HK1245259A1 (zh) 2018-08-24
SG11201708294YA (en) 2017-11-29
AU2016248886B2 (en) 2020-09-10
IL254921B (en) 2021-02-28
EP3283487A1 (en) 2018-02-21
CN107531696A (zh) 2018-01-02
CO2017009989A2 (es) 2018-01-05
WO2016166078A1 (en) 2016-10-20
JP6847851B2 (ja) 2021-03-24
MX373162B (es) 2020-04-21
MX2017013101A (es) 2018-01-30
CA2982217A1 (en) 2016-10-20
CL2017002498A1 (es) 2018-04-20
US20180127414A1 (en) 2018-05-10
BR112017021083A2 (pt) 2018-07-03
PH12017501876A1 (en) 2018-02-26
IL254921A0 (en) 2017-12-31
KR20170137137A (ko) 2017-12-12

Similar Documents

Publication Publication Date Title
CN107531696B (zh) 作为nmda受体调节剂的吡啶并嘧啶酮类及它们的用途
EP3322711B1 (en) Hpk1 inhibitors and methods of using same
EP3707126B1 (en) Ire1 small molecule inhibitors
US10604502B2 (en) Substituted 5-cyanoindole compounds and uses thereof
KR20240006606A (ko) Nav1.8 억제제로서의 아릴 3-옥소피페라진 카르복스아미드 및 헤테로아릴 3-옥소피페라진 카르복스아미드
UA122435C2 (uk) Гетероциклічна сполука
JP6419800B2 (ja) Ｎｍｄａ受容体活性の調節因子としてのチアゾロピリミジノン
TW201710255A (zh) 雜環化合物
WO2019169156A1 (en) Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
US20260078103A1 (en) Isoquinolones as pi3k inhibitors
JP2023550069A (ja) 二環系誘導体を含む阻害剤の遊離塩基の結晶及びその製造方法と使用
JP7812861B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）阻害剤としての三環式ピリミジン
KR20150021120A (ko) 헤테로아릴 화합물 및 이의 이용 방법
JP2021509897A (ja) Ｃｓｆ−１ｒ阻害剤としての複素環式化合物及びその使用
JP7546780B2 (ja) アザヘテロアリール化合物、その調製方法及び使用
JP2022502484A (ja) キナーゼ阻害活性を有する芳香族複素環式化合物
HK1245259B (zh) 作为nmda受体调节剂的吡啶并嘧啶酮类及它们的用途
CN105431146B (zh) 2-卤代-5-炔基-吡啶基烟碱性配体
JP2025537242A (ja) 含窒素スピロ環式化合物、医薬組成物及びその用途
HK1255833B (en) Hpk1 inhibitors and methods of using same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1245259

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant